diversity of providing services to patients suffering from addiction disorders is a harm reduction thought, but...

The diversity of the portfolio of pharmaceutical and non-pharmacological services is an undeniable necessity; however, we must remember that the thinking of harm reduction should govern this process. if we only pay attention to the variety of drugs and their different forms, eventually the noble goal of harm reduction will suffer. in an article that pedersen et al. prepared about the slow-release form of buprenorphine, there are structural and content problems that will be addressed in this article. this article criticizes the rapid change in the provision of harm reduction services and discusses the impact of structural changes in the provision of services and the location of service provision.